Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of viltolarsen versus placebo in ambulant boys with Duchenne muscular dystrophy amenable to exon 53 skipping
NL-OMON52888Phase 3Completed
- Sponsor
- NS Pharma, Inc.
- Start
- Sep 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Viltolarsen with Placebo (2 arms). Primary endpoint: Time to Stand Test at 48 weeks. Started Sep 2020; status: completed.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON52888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52888.